How can I calculate the appropriate insulin dose to achieve a target blood glucose of approximately 120 mg/dL in a patient currently on 15 units of insulin glargine (Lantus) at bedtime and 5 units of rapid‑acting insulin before each meal (total 30 units daily) with persistently high glucose?

Insulin Dose Calculation for Persistent Hyperglycemia

Increase your patient's basal insulin glargine by 2 units every 3 days until fasting glucose reaches 100-120 mg/dL, and simultaneously increase each prandial rapid-acting insulin dose by 1-2 units or 10-15% to address postprandial hyperglycemia. 1

Immediate Titration Strategy

Basal Insulin (Lantus Glargine) Adjustment

Your patient's current 15 units of glargine at bedtime is likely insufficient. The 2025 American Diabetes Association guidelines provide a clear evidence-based titration algorithm: 1

• Increase by 2 units every 3 days to reach fasting plasma glucose goal without hypoglycemia 1
• Target fasting glucose: 100-120 mg/dL (5.5-6.7 mmol/L) 1
• Continue titration until fasting glucose stabilizes in target range 1
• If hypoglycemia occurs, reduce dose by 10-20% 1

The FDA label for Lantus confirms this approach can be safely implemented with appropriate glucose monitoring. 2

Prandial Insulin (Rapid-Acting) Adjustment

Your patient's 5 units three times daily is also inadequate if blood sugars remain persistently high. The guidelines specify: 1

• Increase each prandial dose by 1-2 units OR 10-15% of current dose 1
• Titrate based on postprandial glucose readings 2-4 hours after meals 1
• Address the meal with greatest postprandial glucose excursion first if needed 1

Estimating Total Insulin Requirements

While the guidelines emphasize systematic titration over calculation formulas, research provides useful estimates for context: 3, 4, 5

• Total daily dose estimate: 0.3-0.5 units/kg/day for insulin-naive or low-dose patients 1
• Basal component: Approximately 50% of total daily dose (or 0.2 units/kg) 4, 5
• Prandial component: Remaining 50% divided among three meals 1

For example, if your patient weighs 70 kg:

• Estimated total daily dose: 21-35 units (0.3-0.5 × 70 kg)
• Basal insulin target: 10.5-17.5 units
• Prandial insulin target: 3.5-6 units per meal

Your patient's current 30 units total (15 basal + 15 prandial) falls within this range, but the distribution may be suboptimal if fasting glucose is elevated (suggesting inadequate basal) or postprandial glucose is elevated (suggesting inadequate prandial coverage). 1

Systematic Titration Protocol

Week-by-week approach: 1

1. Focus on fasting glucose first: Titrate basal insulin by 2 units every 3 days until fasting glucose 100-120 mg/dL 1
2. Then address postprandial glucose: Once fasting glucose is controlled, increase prandial doses by 1-2 units at meals where 2-hour postprandial glucose exceeds target 1
3. Reassess every 3-6 months to avoid therapeutic inertia 1

Critical Monitoring Points

• Check fasting glucose daily during basal titration 1
• Monitor for hypoglycemia: Any glucose <70 mg/dL requires dose reduction by 10-20% 1
• Assess for overbasalization: If basal dose exceeds 0.5-1.0 units/kg/day without achieving target, consider adding GLP-1 RA rather than continuing to escalate insulin 1, 6
• Watch for elevated bedtime-to-morning differential: This signals inadequate basal coverage 1
• Monitor postprandial-to-preprandial differential: This indicates need for prandial adjustment 1

Common Pitfalls to Avoid

Do not use sliding scale insulin alone in patients already on basal-bolus therapy—this approach is associated with worse glycemic control and is discouraged in guidelines. 1 Your patient needs scheduled dose increases, not reactive corrections.

Avoid therapeutic inertia: The guidelines explicitly warn against waiting too long between dose adjustments. 1 If glucose remains elevated after 3 days, increase the dose—don't wait weeks.

Don't continue escalating basal insulin indefinitely: If basal insulin reaches approximately 0.5-1.0 units/kg/day without adequate fasting glucose control, this represents overbasalization and warrants adding other agents (GLP-1 RA) rather than further basal increases. 1, 6

Alternative Consideration

If your patient is not already on a GLP-1 receptor agonist and A1C remains above goal despite insulin titration, strongly consider adding a GLP-1 RA before continuing to escalate insulin doses, as this combination reduces hypoglycemia risk and may improve overall outcomes. 1